The Changing Landscape of HER2-Positive Breast Cancer
For decades, a diagnosis of HER2-positive breast cancer was met with significant concern. This subtype, characterized by the over-expression of the Human Epidermal Growth Factor Receptor 2 (HER2) protein, was historically known for being aggressive and having a poor prognosis. The advent of HER2-targeted therapies, starting with trastuzumab, revolutionized treatment, turning a once-deadly diagnosis into a highly manageable one. However, the cornerstone of this success has traditionally been a combination of targeted therapy and intensive chemotherapy.
While chemotherapy is effective, it is also toxic. Patients often endure hair loss, severe nausea, neuropathy, and long-term risks to heart and bone marrow health. As our understanding of tumor biology deepens, a pivotal question has emerged: Do all HER2-positive patients truly need chemotherapy? Or can we identify a subset of patients who can achieve a cure using only targeted biological agents and immunotherapy?
